Filing Details
Neumora Therapeutics, Inc. (NASDAQ:NMRA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNASDAQ:NMRA
Neumora Therapeutics, Inc. (NMRA) Files Quarterly Report for Q0
Neumora Therapeutics, Inc. (NASDAQ:NMRA) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 14, 2026.
At publication ·
What changed
Neumora Therapeutics, Inc. (NASDAQ:NMRA) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Neumora Therapeutics (NASDAQ: NMRA) filed its Q0 2026 quarterly report on August 14, 2026, containing unaudited financial statements and management commentary on business performance.
- The company's stock trades at $1.60 per share with a market capitalization of $346.6 million.
- The 10-Q filing provides timely information about emerging trends, updated risk factors, and changes in business conditions, though with less detail than the annual 10-K report.
Market Context
Neumora Therapeutics, Inc.'s stock currently trades at $1.60 with a market capitalization of $346.6M.
The 10-Q provides Neumora Therapeutics, Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Neumora Therapeutics, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View NMRA Stock Page
Frequently Asked Questions
Where can I read NMRA's SEC filings?
Browse all filings on our NMRA SEC filings page.
What types of SEC filings does Neumora Therapeutics, Inc. file?
Public companies like Neumora Therapeutics, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.